What is Alector?
Founded in 2013, Alector operates at the intersection of immunology and neuroscience, focusing on the preventative development of therapies for complex conditions such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. By leveraging the body's immune system to combat neurodegeneration, the company has established itself as a high-authority player in the biotech sector. Its business model relies on rigorous preclinical and clinical research, supported by a robust network of institutional backers and corporate venture partners who prioritize long-term medical breakthroughs over short-term gains.
How much funding has Alector raised?
Alector has raised a total of $430.5M across 6 funding rounds:
Series C
$32M
Series D
$29.5M
Series E
$133M
Stock Offering
$176M
Debt
$50M
Debt
$10M
Series C (2015): $32M with participation from OrbiMed, Polaris Partners, MRL Ventures Fund, GV, Topspin Partners, and Mission Bay Capital
Series D (2016): $29.5M led by Dementia Discovery Fund, AbbVie, and Amgen Business Development
Series E (2018): $133M supported by GV, Perceptive Advisors, New Leaf Venture Partners, AbbVie Ventures, OrbiMed, MRL Ventures, Amgen Business Development, Deerfield Management, Mission Bay Capital, Casdin Capital, Section 32, Federated Kaufmann Fund, Polaris Partners, Lilly Asia Ventures, Foresite Capital, the Dementia Discovery Fund, and Euclidean Capital
Stock Issuance/Offering (2019): $176M, investors not publicly disclosed
Debt (2024): $50M backed by Hercules Capital
Debt (2024): $10M with participation from Hercules Capital
Key Investors in Alector
OrbiMed
OrbiMed is a specialized healthcare investment firm managing capital across biopharmaceuticals and medical devices, known for its multi-stage strategy that supports companies from early-stage ventures to established organizations.
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational biotech and healthcare companies, providing deep operational expertise and coaching to foster long-term innovation.
GV
GV is a global venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences and frontier technology innovations.
What's next for Alector?
With the recent influx of capital, Alector is well-positioned to accelerate its pipeline of therapeutic candidates. The company's strategic roadmap likely involves advancing its lead programs through critical clinical milestones while expanding its research infrastructure. Given the high-stakes nature of neurodegenerative drug development, the firm will likely continue to utilize its capital to strengthen its intellectual property portfolio and foster collaborative partnerships with global pharmaceutical entities, ensuring that its innovative solutions move efficiently toward commercialization and patient impact.
See full Alector company page
